Loader

Pathways

PathWhiz ID Pathway Meta Data

PW127284

Pw127284 View Pathway
disease

UMP Synthase Deficiency (Orotic Aciduria)

Homo sapiens
Orotic aciduria, also known as UMP synthase deficiency, is an autosomal recessive disorder of pyrimidine metabolism caused by a defective uridine monophosphate synthetase (UMPS). UMPS is a multifunctional protein which carries out the functions of both orotate phosphoribosyltransferase (OPRT) and orotidine 5'-phosphate decarboxylase (ODC). UMPS catalyzes the conversion of orotic acid into uridine monophosphate (UMP) which is a nucleotide incorporated into ribonucleic acid (RNA). This disease is characterized by a very large accumulation of orotic acid in the urine, occasionally causing urinary obstruction. Symptoms of the disease include megaloblastic anemia as well as retarded growth and development.

PW145957

Pw145957 View Pathway
drug action

Umeclidinium Drug Metabolism Action Pathway

Homo sapiens

PW176159

Pw176159 View Pathway
metabolic

Umbralisib Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Umbralisib are predicted with biotransformer.

PW146902

Pw146902 View Pathway
drug action

Umbralisib Drug Metabolism Action Pathway

Homo sapiens

PW144712

Pw144712 View Pathway
drug action

Ulobetasol Drug Metabolism Action Pathway

Homo sapiens

PW127826

Pw127826 View Pathway
drug action

Ulobetasol Action Pathway

Homo sapiens
Ulobetasol, also known as Halobetasol, is a highly potent corticosteroid used to treat corticosteroid-responsive dermatoses. This drug is available as a topical cream, foam, spray, or ointment. Ulobetasol is a glucocorticoid receptor agonist and is structurally related to clobetasol. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. This drug also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.

PW176158

Pw176158 View Pathway
metabolic

Ulipristal Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Ulipristal are predicted with biotransformer.

PW145857

Pw145857 View Pathway
drug action

Ulipristal Drug Metabolism Action Pathway

Homo sapiens

PW244655

Pw244655 View Pathway
metabolic

Uliana1

Saccharomyces cerevisiae

PW124408

Pw124408 View Pathway
metabolic

UDP-N-acetyl-D-Glucosamine

Pseudomonas aeruginosa